464
Participants
Start Date
January 1, 2023
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2028
Re-resection
Resection of the recurrent tumor
Temozolomide
Re-challenge Temozolomide chemotherapy
Lomustine
Second line chemotherapy with Lomustine
Re-irradiation
Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
Experimental therapy
Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
Best supportive care
Best supportive care, focused on alleviating symptoms
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
University Hospital Leuven, Leuven
RECRUITING
University Hospital Heidelberg, Heidelberg
NOT_YET_RECRUITING
Technical University Munich, Munich
NOT_YET_RECRUITING
Inselspital Universitätsspital Bern, Bern
RECRUITING
Erasmus MC, Rotterdam
RECRUITING
Medical Center Haaglanden, The Hague
Collaborators (1)
Haaglanden Medical Centre
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER
University Hospital Heidelberg
OTHER
Technical University of Munich
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
Massachusetts General Hospital
OTHER
University of California, San Francisco
OTHER
Jasper Gerritsen
OTHER